{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:21:58Z","timestamp":1792707718300,"version":"4.5.0"},"reference-count":33,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"unspecified","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie Inc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2025,12,11]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Patients with rheumatoid (RA) or psoriatic (PsA) arthritis can experience debilitating pain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Post hoc analyses of phase 3, double-blind studies in patients with active disease despite treatment (SELECT-COMPARE, SELECT-PsA 1) assessed the effects of upadacitinib or adalimumab versus placebo on pain in patients with attenuation of inflammation (AoI) versus remaining inflammation at weeks 12 and 24\/26 (PsA\/RA). Further, a mediation analysis assessed the direct\/indirect effect of treatment on pain using the Patient\u2019s Global Assessment of pain (PtGA) and 28 tender joint count (TJC28) at weeks 2\/12\/26 in RA, and weeks 16\/24 in PsA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In patients with RA+AoI, PtGA scores improved more with upadacitinib (least squares mean change, \u201342.9) versus adalimumab (\u201334.7 (p&lt;0.05)) or placebo (\u201333.1 (p&lt;0.05)) at week 12 from baseline; improvements were similar across groups by week 26. For PsA+AoI, improvement was greater with upadacitinib (week 12, \u20132.7; week 24, \u20133.8) versus placebo (\u22121.8 (p&lt;0.05); \u20132.8 (p&lt;0.001), respectively) and similar to adalimumab (\u20132.8, \u20133.6). For RA, the direct effect on pain was nearly two times greater with upadacitinib versus placebo compared with adalimumab at weeks 12\/26. For PsA, total effects on pain (TJC28 improvement) at weeks 16\/24 were greater with upadacitinib (2.16 and 2.30) and adalimumab (1.35 and 1.71) versus placebo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Upadacitinib effectively reduced pain in active RA and PsA, including in patients with AoI. The greater pain relief observed in RA with upadacitinib versus adalimumab might indicate both direct (relieving non-inflammatory pain) and indirect (suppressing inflammation) effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/rmdopen-2025-005867","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T13:40:14Z","timestamp":1767879614000},"page":"e005867","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Effects of upadacitinib or adalimumab on pain in rheumatoid arthritis and psoriatic arthritis: results from randomised phase 3 studies"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7766-6167","authenticated-orcid":false,"given":"Peter C","family":"Taylor","sequence":"first","affiliation":[{"name":"Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Kavanaugh","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Autoimmunity and Inflammation, University of California San Diego, La Jolla, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Bessette","sequence":"additional","affiliation":[{"name":"Laval University, Qu\u00e9bec City, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8845-4274","authenticated-orcid":false,"given":"Bruno","family":"Fautrel","sequence":"additional","affiliation":[{"name":"Piti\u00e9-Salp\u00eatri\u00e8re Hospital, Sorbonne University, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1111-8218","authenticated-orcid":false,"given":"Tsutomu","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Keio University, Tokyo, Japan"},{"name":"Department of Rheumatology and Applied Immunology\/Clinical Immunology, Saitama Medical University, Saitama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Garrison","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianming","family":"Gao","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Lippe","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Caballero","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Phillips","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6620-0457","authenticated-orcid":false,"given":"Philip J","family":"Mease","sequence":"additional","affiliation":[{"name":"University of Washington, Seattle, Washington, USA"},{"name":"Providence Swedish Medical Center, Seattle, WA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"key":"2026010805400662000_12.1.e005867.1","doi-asserted-by":"crossref","first-page":"103423","DOI":"10.1016\/j.autrev.2023.103423","article-title":"Residual pain in rheumatoid arthritis: Is it a real problem?","volume":"22","author":"Sarzi-Puttini","year":"2023","journal-title":"Autoimmun Rev"},{"key":"2026010805400662000_12.1.e005867.2","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s40744-022-00436-x","article-title":"Experiences and Treatment Preferences in Patients With Psoriatic Arthritis: A Cross-Sectional Study in the ArthritisPower Registry","volume":"9","author":"Ogdie","year":"2022","journal-title":"Rheumatol Ther"},{"key":"2026010805400662000_12.1.e005867.3","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/RHU.0000000000001799","article-title":"Current Medication Practices and Preferences Among Patients With Psoriatic Arthritis","volume":"28","author":"Schwartzman","year":"2022","journal-title":"J Clin Rheumatol"},{"key":"2026010805400662000_12.1.e005867.4","doi-asserted-by":"crossref","first-page":"e351","DOI":"10.1016\/S2665-9913(23)00094-2","article-title":"Pain in the joints and beyond; the challenge of rheumatoid arthritis","volume":"5","author":"Taylor","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"2026010805400662000_12.1.e005867.5","doi-asserted-by":"crossref","first-page":"100537","DOI":"10.1016\/j.bjpt.2023.100537","article-title":"Phenotyping nociceptive, neuropathic, and nociplastic pain: who, how, & why?","volume":"27","author":"Nijs","year":"2023","journal-title":"Braz J Phys Ther"},{"key":"2026010805400662000_12.1.e005867.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2020.10.008"},{"key":"2026010805400662000_12.1.e005867.7","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-022-00482-5"},{"key":"2026010805400662000_12.1.e005867.8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0180014","article-title":"Pain and pain mechanisms in patients with inflammatory arthritis: A Danish nationwide cross-sectional DANBIO registry survey","volume":"12","author":"Rifbjerg-Madsen","year":"2017","journal-title":"PLoS One"},{"key":"2026010805400662000_12.1.e005867.9","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23031246","article-title":"Janus Kinase Inhibitors Improve Disease Activity and Patient-Reported Outcomes in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of 24,135 Patients","volume":"23","author":"T\u00f3th","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2026010805400662000_12.1.e005867.10","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s11914-018-0473-5","article-title":"Mechanisms for Joint Pain in Rheumatoid Arthritis (RA): from Cytokines to Central Sensitization","volume":"16","author":"Zhang","year":"2018","journal-title":"Curr Osteoporos Rep"},{"key":"2026010805400662000_12.1.e005867.11","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1002\/art.41032","article-title":"Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial","volume":"71","author":"Fleischmann","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2026010805400662000_12.1.e005867.12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30419-2"},{"key":"2026010805400662000_12.1.e005867.13","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218870"},{"key":"2026010805400662000_12.1.e005867.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022516"},{"key":"2026010805400662000_12.1.e005867.15","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-002049","article-title":"Effect of upadacitinib on reducing pain in patients with active psoriatic arthritis or ankylosing spondylitis: post hoc analysis of three randomised clinical trials","volume":"8","author":"McInnes","year":"2022","journal-title":"RMD Open"},{"key":"2026010805400662000_12.1.e005867.16","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215764"},{"key":"2026010805400662000_12.1.e005867.17","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8060831","article-title":"Achieving Pain Control in Rheumatoid Arthritis with Baricitinib or Adalimumab Plus Methotrexate: Results from the RA-BEAM Trial","volume":"8","author":"Taylor","year":"2019","journal-title":"J Clin Med"},{"key":"2026010805400662000_12.1.e005867.18","doi-asserted-by":"publisher","DOI":"10.3758\/BRM.40.3.879"},{"key":"2026010805400662000_12.1.e005867.19","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s40744-024-00660-7","article-title":"Exploring the Effects of Ixekizumab on Pain in Patients with Ankylosing Spondylitis Based on Objective Measures of Inflammation: Post Hoc Analysis from a Large Randomized Clinical Trial","volume":"11","author":"de Vlam","year":"2024","journal-title":"Rheumatol Ther"},{"key":"2026010805400662000_12.1.e005867.20","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(00)00339-0"},{"key":"2026010805400662000_12.1.e005867.21","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(01)00349-9"},{"key":"2026010805400662000_12.1.e005867.22","first-page":"2016","article-title":"Minimal disease activity for rheumatoid arthritis: a preliminary definition","volume":"32","author":"Wells","year":"2005","journal-title":"J Rheumatol"},{"key":"2026010805400662000_12.1.e005867.23","first-page":"1674","article-title":"Assessment of pain in rheumatoid arthritis: minimal clinically significant difference, predictors, and the effect of anti-tumor necrosis factor therapy","volume":"34","author":"Wolfe","year":"2007","journal-title":"J Rheumatol"},{"key":"2026010805400662000_12.1.e005867.24","unstructured":"IMMPACT . Initiative on methods, measurement, and pain assessment in clinical trials. Available: https:\/\/www.immpact.org\/ [Accessed 12 Sep 2024]."},{"key":"2026010805400662000_12.1.e005867.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2007.09.005"},{"key":"2026010805400662000_12.1.e005867.26","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003839","article-title":"Impact of filgotinib on pain control in the phase 3 FINCH studies","volume":"10","author":"Taylor","year":"2024","journal-title":"RMD Open"},{"key":"2026010805400662000_12.1.e005867.27","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001994","article-title":"Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy","volume":"8","author":"Taylor","year":"2022","journal-title":"RMD Open"},{"key":"2026010805400662000_12.1.e005867.28","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002478","article-title":"The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis","volume":"8","author":"Dougados","year":"2022","journal-title":"RMD Open"},{"key":"2026010805400662000_12.1.e005867.29","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8091394","article-title":"Effect of Baricitinib and Adalimumab in Reducing Pain and Improving Function in Patients with Rheumatoid Arthritis in Low Disease Activity: Exploratory Analyses from RA-BEAM","volume":"8","author":"Fautrel","year":"2019","journal-title":"J Clin Med"},{"key":"2026010805400662000_12.1.e005867.30","unstructured":"Mease PJ , Eder L , Ogdie A . Assessment of direct and indirect impact on pain and fatigue outcomes in a phase 2 clinical trial of deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in patients with active PsA: a mediation analysis. ACR 2023."},{"key":"2026010805400662000_12.1.e005867.31","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/acr.25358","article-title":"Prevalence of Fibromyalgia and Widespread Pain in Psoriatic Arthritis: Association With Disease Severity Assessment in a Large US Registry","volume":"76","author":"Mease","year":"2024","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026010805400662000_12.1.e005867.32","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000388"},{"key":"2026010805400662000_12.1.e005867.33","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000001023"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2025-005867","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T13:40:17Z","timestamp":1767879617000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2025-005867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,8]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/rmdopen-2025-005867"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2025-005867","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}